<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552641</url>
  </required_header>
  <id_info>
    <org_study_id>TIMESO</org_study_id>
    <nct_id>NCT02552641</nct_id>
  </id_info>
  <brief_title>Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole</brief_title>
  <official_title>Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is assess whether the various forms of triple regimen of
      administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and
      any independent mealtime) influence the rate of eradication of this bacterium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV, open, randomized, prospective study.

        -  Length of experience: 180 days.

        -  06 visits.

        -  Evaluation of the efficacy of differences regimens of administration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of H pylori eradication</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects in each of the forms of triple therapy administration and compare them</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food effect</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarythromycin</intervention_name>
    <arm_group_label>Test 1</arm_group_label>
    <arm_group_label>Test 2</arm_group_label>
    <arm_group_label>Test 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes;

          -  Age greater than or equal to 18 and less than or equal to 50 years;

          -  Participant diagnosed with type dyspepsia epigastric pain carriers of Helicobacter
             pylori infection, according to the classification of ROME III;

          -  Ability to understand and consent to participate in this clinical study, manifested by
             reading, understanding and signing of the Informed Consent (IC).

        Exclusion Criteria:

          -  Any finding of clinical observation (clinical evaluation / physical) that is
             interpreted by the investigator as a medical risk to participate in the clinical
             trial;

          -  Any laboratory examination found that the investigator doctor considers a risk to the
             research participant for their participation in the clinical trial;

          -  Known hypersensitivity to the drug components used during the study;

          -  Women in pregnancy or breastfeeding period;

          -  Women in reproductive age who do not agree to use acceptable methods of contraception
             (oral contraceptives, injectable contraceptive, IUD, hormonal implants, barrier
             methods, abstinence, hormonal patch and tubal ligation); except surgically sterile
             (bilateral oophorectomy or hysterectomy);

          -  Participating in the research that has participated in clinical trial protocols in the
             last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J),
             unless the investigator considers that there may be direct benefit to it;

          -  Party that has some kinship to the second degree or bond with employees or employees
             of Sponsor and Research Center;

          -  Patients with predominant symptoms of reflux or irritable bowel syndrome, warning
             symptoms, peptic ulcer history or previous surgery in the upper segment of the
             gastrointestinal tract;

          -  Patients with prior treatment history of eradication of Helicobacter pylori;

          -  Patients with kidney, liver or heart failure;

          -  Patients with past or current history of alcohol abuse;

          -  Patients with a history of use of antibiotics or bismuth in the 4 weeks prior to study
             entry, PPIs or H2 blockers, NSAIDs or aspirin in the last two weeks;

          -  Patients whose endoscopy show changes except hyperemic gastritis, erosive gastritis
             den considering the maximum of 5 erosions in this location or hiatal hernia;

          -  Patients whose ultrasonography show hepato-biliopancreatic changes except steatosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Decio Chinzon, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Ecclissato, Md</last_name>
    <phone>55.19.38879433</phone>
    <email>christina.ecclissato@ems.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Decio Chinzon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Decio Chinzon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>September 16, 2015</last_update_submitted>
  <last_update_submitted_qc>September 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

